DexCom received a warning letter from the Food and Drug Administration following inspections of its San Diego and Mesa, Ariz.

周一，尽管DexCom（NASDAQ:DXCM）收到FDA警告函，BTIG分析师仍维持该公司股票的买入评级和120.00美元的目标价。该股目前交易价格为77.84美元，过去一周大跌9.5%，InvestingPro数据显示该股已处于超卖状态。DexCom在8-K文件中披露，FDA在2024年10月至11月期间对其位于加利福尼亚州圣地亚哥的制造设施，以及2024年6月对亚利桑那州梅萨的制造设施进行检 ...

Medical device maker Dexcom said it has received a warning letter from the U.S. Food and Drug Administration following ...

DexCom said that on Tuesday it received a warning letter from the U.S. FDA following inspections at its facilities in San ...

In a regulatory filing, DexCom (DXCM) disclosed that on March 4, the company received a warning letter from the U.S. FDA following inspections ...

Dexcom (Nadsaq:DXCM) announced today that it received a warning letter from the FDA following inspections of two company ...

The U.S. Department of Agriculture has dissolved two key food safety advisory committees, sparking concern over government ...

DexCom (NasdaqGS:DXCM) recently received a warning letter from the FDA, which pointed out issues in manufacturing processes and quality management. While these regulatory developments did not impact ...

Piper Sandler analyst Matthew O’Brien maintained a Buy rating on Dexcom (DXCM – Research Report) today and set a price target of $100.00. The ...

The latest health news includes Johnson & Johnson halting testing on a depression drug, USDA eliminating food safety advisory ...

(Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, today announced that its next-generation ...